Spyre Therapeutics Inc <SYRE.O>: JonesTrading cuts target price to $121 from $140
SYRE•Related News
J.M. Smucker forecasts smaller-than-expected annual sales decline on steady coffee demand
SJM•
American Express targets USD 4 billion-8 billion unsecured term debt issuance in 2026 funding plan
AXP•
OPAL Fuels completes Goshen, California fueling station upgrade, adds 2 million GGE capacity over decade
OPAL•
Vivmark Residential <VMRK.N>: Morgan Stanley resumes coverage with overweight rating; target price $75
VMRK•
Wetour Robotics enters at-the-market share sales agreement with Rodman & Renshaw
WETO•